Apigenin is a plant compound from chamomile, parsley and celery, sold as an evening capsule on two promises: that it calms the nervous system, and that it protects a cellular fuel molecule that falls with age. No study of purified apigenin has reported a health outcome in people. Everything encouraging comes from cells, animals, or whole chamomile extract. Cheap, plausible, and unproven in either direction. (Full Review)

Protocol

Standard dose

50 mg once daily

The dose used in essentially all consumer protocols and in the completed sepsis pilot trial. No dose-ranging study in healthy adults exists.

Timing

30–60 min before bed

Universal across practitioner and popular protocols; follows from the sedative rather than the metabolic rationale.

Single versus split dosing

Single evening dose

Splitting undermines the only rationale with human support, since a daytime dose delivers sedation when it is not wanted.

Time to effect

Anxiety

8 weeks

Greater symptom reduction than placebo with chamomile extract, sustained through 26 weeks of continuation.

Sedative effect

First night

Felt within 30–60 minutes, if present; the randomised insomnia trial of chamomile found no change in sleep measures.

Metabolic or ageing-related effect

No established timeline

No human study has measured one; a 12-week reassessment point is where discontinuation is considered.

Benefits

Medium: Improved skin density, elasticity and fine wrinkling with topical use

Low: Reduced anxiety, with mixed effects on sleep itself; reduced menopausal symptoms with chamomile extract; lower testosterone in polycystic ovary syndrome with chamomile extract; fewer recurrences of colorectal neoplasia after resection; lower all-cause mortality with a flavonoid-rich diet

Speculative: Preservation of NAD⁺ through CD38 inhibition; suppression of the worn-out-cell secretome; antitumour activity; cognitive protection; cardiometabolic improvement

Contraindications

Pregnant and breastfeeding women

Documented chamomile or daisy-family allergy, including mugwort or ragweed cross-sensitisation, when the product is chamomile-derived

Solid-organ transplant recipients on anti-rejection medicines such as tacrolimus or ciclosporin

Hormone-receptor-positive breast or prostate cancer on endocrine therapy

Child-Pugh Class B or C liver impairment

Anyone within two weeks of scheduled surgery

Key Interactions

Sedatives and central nervous system depressants (benzodiazepines, Z-drugs such as zolpidem, opioids, gabapentinoids such as pregabalin, alcohol)

Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel, aspirin)

Narrow-therapeutic-index substrates of CYP3A4 and P-glycoprotein (tacrolimus, ciclosporin, dasatinib, some statins)

Serotonergic antidepressants cleared hepatically (venlafaxine, sertraline)

Losartan and other medicines the liver must activate

Over-the-counter sedating antihistamines (diphenhydramine, doxylamine) and melatonin

Non-steroidal anti-inflammatory drugs

Supplements with additive sedation (valerian, passionflower, magnesium, L-Theanine, glycine, kava)

Supplements with additive antiplatelet effect (fish oil, ginkgo, garlic, high-dose vitamin E, quercetin)

Nicotinamide riboside and nicotinamide mononucleotide

Risk & Side Effects

Low: Allergic reactions, including anaphylaxis, to chamomile-derived preparations; falling body weight and blood pressure on prolonged use; sedation carried into the following day

Speculative: Raised blood levels of co-administered medicines; altered sex-hormone synthesis; interference with thyroid hormone coupling; impaired platelet aggregation

Monitoring

Marker	Target	Why
hs-CRP	Below 1.0 mg/L	Tracks the general inflammation the anti-inflammatory rationale targets
Fasting insulin	2–5 µIU/mL	Earliest signal of the glucose-handling effect claimed from animal work
HbA1c	5.0–5.4%	Confirms or refutes any sustained glucose effect
ALT	10–19 U/L in women, 10–26 U/L in men	Safety check on a heavily liver-metabolised compound
TSH	0.5–2.0 mIU/L	Safety check against the flavone effect on thyroid hormone coupling seen in rodents
Total testosterone (men) or oestradiol (women)	No apigenin-specific target; change from own baseline	Watches the unresolved effect on steroid-synthesising enzymes
Platelet count and, if anticoagulated, INR	Platelets 150–400 ×10⁹/L; INR within the target set for the indication	Safety check on the theoretical platelet effect

Cadence: Monthly home blood pressure and weight; blood panel at 12 weeks, then every 6–12 months if use continues; for a narrow-therapeutic-index medicine, that drug's level or clotting time 2–4 weeks after starting and after any dose change.

Qualitative Assessment

Time to fall asleep, judged over a week rather than a single night
Number of remembered night-time awakenings
Morning alertness and absence of residual sedation in the first waking hour
Daytime anxiety and rumination, ideally with a repeated short self-rating scale
Dream intensity, which some users report changes when apigenin is combined with theanine
Overall energy and cognitive clarity through the afternoon

Apigenin for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment